

Karen M Macdonald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4582848/publications.pdf>

Version: 2024-02-01

36
papers

785
citations

567281

15
h-index

526287

27
g-index

36
all docs

36
docs citations

36
times ranked

956
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. <i>Future Oncology</i> , 2022, 18, 363-373.	2.4	2
2	Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-8.	1.9	0
3	“Real-world” effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 73-83.	3.0	5
4	Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. <i>Journal of Medical Economics</i> , 2021, 24, 743-756.	2.1	9
5	Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. <i>Current Medical Research and Opinion</i> , 2021, 37, 367-375.	1.9	2
6	Cost-efficiency analysis of conversion from reference pegfilgrastim to its biosimilar (pegfilgrastim-jmdb) and expanded access to food and transportation support for Medicare/Medicaid patients within the CMS Oncology Care Model. <i>Journal of Clinical Oncology</i> , 2021, 39, e18837-e18837.	1.6	3
7	Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2021, 106, 106591.	0.8	7
8	Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. <i>Future Oncology</i> , 2021, 17, 4561-4570.	2.4	4
9	Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. <i>Journal of Medical Economics</i> , 2021, 24, 598-606.	2.1	5
10	Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. <i>Journal of Medical Economics</i> , 2021, 24, 71-83.	2.1	6
11	Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. <i>Journal of Medical Economics</i> , 2020, 23, 28-36.	2.1	19
12	Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. <i>Journal of Medical Economics</i> , 2020, 23, 1466-1476.	2.1	15
13	Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study). <i>Clinical Ophthalmology</i> , 2020, Volume 14, 4173-4185.	1.8	21
14	Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. <i>Journal of Medical Economics</i> , 2020, 23, 856-863.	2.1	17
15	Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS Study. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 1473-1481.	1.8	4
16	Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 553-569.	3.0	56
17	Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria. <i>JAMA Dermatology</i> , 2019, 155, 29.	4.1	81
18	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day (24h), per-guidelines (24-72h), and (22h): findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2019, 27, 2301-2312.		

#	ARTICLE	IF	CITATIONS
19	Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of "real-world" evidence. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 425-448.	3.1	53
20	Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2018, 21, 606-609.	2.1	8
21	"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1362-1370.e2.	3.8	83
22	Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. <i>Future Oncology</i> , 2017, 13, 2285-2295.	2.4	25
23	Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2017, 20, 1083-1093.	2.1	30
24	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. <i>International Journal of Chronic Diseases</i> , 2017, 2017, 1-11.	1.0	1
25	Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. <i>International Journal of Ophthalmology</i> , 2017, 10, 81-90.	1.1	18
26	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016, 24, 911-925.	2.2	62
27	Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study. <i>Clinical Therapeutics</i> , 2015, 37, 842-857.	2.5	48
28	Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium. <i>British Journal of General Practice</i> , 2015, 65, e9-e15.	1.4	8
29	Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. <i>Future Oncology</i> , 2014, 10, 1599-1609.	2.4	50
30	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Adherent vs Nonadherent Hypertensive Patients: Pooled Analysis of 6 Studies With 14,646 Evaluable Patients. <i>Journal of Clinical Hypertension</i> , 2013, 15, 663-673.	2.0	10
31	Biosimilars in 3D. <i>Bioengineered</i> , 2013, 4, 203-206.	3.2	14
32	Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. <i>Clinical Ophthalmology</i> , 2013, 7, 1849.	1.8	54
33	Effectiveness of Amlodipine-Valsartan Single-Pill Combinations: Hierarchical Modeling of Blood Pressure and Total Cardiovascular Disease Risk Outcomes (the EXCELLENT Study). <i>Annals of Pharmacotherapy</i> , 2011, 45, 727-739.	1.9	16
34	Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: The BSCORE study. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 428-434.	1.6	6
35	Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. <i>Vascular Health and Risk Management</i> , 2011, 7, 209.	2.3	16
36	Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the Preview Study). <i>Annals of Pharmacotherapy</i> , 2009, 43, 849-861.	1.9	15